drugset
drugset / Trial / NCT01405248

Butylphthalide for Preventing Restenosis After Intracranial and Extracranial Artery Stenting

NCT01405248 ↗

Phase 3 Completed 100 enrolled Jinling Hospital, China CSPC-NBP Pharmaceutical Co., Ltd. · collab
RandomizedParallel-groupQuadruple-blindPrevention

Summary

The purpose of this study is to determine whether butylphthalide are effective for Preventing Restenosis after Intracranial and Extracranial Artery Stenting

Timeline

Start
2011-07
Primary completion
2014-01
Completion
2014-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Butylphthalide Small molecule 20 mg Oral

Indications

coronary restenosis